Becton Dickinson - 100 and on its way to outgrow the US
This article was originally published in Clinica
Becton Dickinson will reach the venerable age of 100 in September. One of the world's top 10 medtech companies, the US medical supplies and diagnostics company plans to celebrate the centenary quietly with its 18,000 staff. Festivities will be led by Harry Becton, son of the founder, who represents the past and by chief executive Clateo Castellini, who will discuss the next 100 years.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.